Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy
Novo Nordisk’s rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates […]
Novo Nordisk’s rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates […]
Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light […]
Date: July 12, 2021 Issue #: 1628 Summary: The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat […]
Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine […]
Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine […]
Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The […]
Copyright © 2024 | WordPress Theme by MH Themes